XML 114 R82.htm IDEA: XBRL DOCUMENT v3.19.1
Collaborative and Other Relationships Collaborative and Other Relationships - Equity Method Investments (Details)
$ in Millions, ₩ in Billions
3 Months Ended
Mar. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2018
KRW (₩)
Mar. 31, 2018
USD ($)
Mar. 31, 2019
KRW (₩)
Dec. 31, 2018
KRW (₩)
Nov. 07, 2018
USD ($)
Jun. 30, 2018
Schedule of Equity Method Investments [Line Items]                
Our share of Samsung Bioepis gains (losses) $ (28.7)     $ 0.0        
Collaboration profit (loss) sharing 58.1     42.5        
Total revenues $ 3,489.8     3,131.1        
Samsung Bioepis                
Schedule of Equity Method Investments [Line Items]                
Percentage of stake in entity               5.00%
Percentage of stake in entity maximum 49.90%       49.90%      
Payments to acquire additional investment in equity method investment   $ 676.6 ₩ 759.5          
Amortization of basis differences             $ 675.0  
Loss recorded on Samsung Bioepis joint venture $ 28.7              
Our share of Samsung Bioepis gains (losses) 14.0              
Amortization of basis differences 14.7              
Investment in Samsung Bioepis $ 642.1 $ 680.6     ₩ 729.9 ₩ 759.5    
Biogen share of co-promotion profits or losses 50.00%              
Collaboration profit (loss) sharing $ 58.1     43.8        
Collaborative arrangement | Samsung Bioepis                
Schedule of Equity Method Investments [Line Items]                
Total revenues $ 24.8     $ 17.9        
Inventory | Samsung Bioepis                
Schedule of Equity Method Investments [Line Items]                
Amortization of basis differences             115.0  
Equity method investment basis difference amortization period 1 year 6 months              
Developed technology | Samsung Bioepis                
Schedule of Equity Method Investments [Line Items]                
Amortization of basis differences             615.0  
Equity method investment basis difference amortization period 15 years              
In Process Research and Development | Samsung Bioepis                
Schedule of Equity Method Investments [Line Items]                
Amortization of basis differences             170.0  
Deferred tax liability | Samsung Bioepis                
Schedule of Equity Method Investments [Line Items]                
Amortization of basis differences             $ 225.0